Introduction. Juvenile idiopathic arthritis (JIA) is a persistent type of arthritis with no defined cause that starts before the age of 16 years and lasts for at least 6 weeks.
The objective of the study was to determine the clinical and laboratory efficacy of golimumab treatment in patients with JIA.
Material and methods. The study took place in the Division of Rheumatology, Public Healthcare Institution – Mother and Child Institute, Chisinau, Republic of Moldova. The parents of the patients signed the written consent to participate in the study. The study was approved by the Ethics Committee of the institute. The inclusion and exclusion criteria for patients to undergo the biological treatment were according to ACR (American College of Rheumatology) recommendations. This study included 17 children with JIA, in whom golimumab was administered every month. The number of painful and swollen joints, the global evaluation of the disease by the doctor (GEDD) and by the patient (GEDP), as well as via the Childhood Health Assessment Questionnaire (CHAQ), were determined. Furthermore, paraclinical tests, that included complete blood count and C-reactive protein (CRP), were determined.
Results. Children treated with golimumab exhibited fewer painful and swollen joints, as well as the GEDD, GEDP, and CHAQ scores. Moreover, a decrease of the erythrocyte sedimentation rate (ESR) and CRP was observed.
Conclusions. Children with JIA treated with golimumab showed a considerable clinical improvement and the paraclinical indices revealed a lower active inflammatory response.
Keywords: juvenile idiopathic arthritis, golimumab, inflammatory markers.
Full text sources https://doi.org/10.31688/ABMU.2022.57.2.02
How to cite
Email to Author
Address for correspondence:
Ninel REVENCO
Department of Pediatrics, State University of Medicine and Pharmacy ”Nicolae Testemitanu”, Division of Rheumatology, Public Healthcare Institution – Mother and Child Institute, Chisinau, Republic of Moldova
Email: ninel.revenco@usmf.md; Phone: +373 68889926
